Dapagliflozin 10mg + Vildagliptin 100mg Sustained Release Tablets are an oral solid pharmaceutical form, comprising of Dapagliflozin 10mg and Vildagliptin 100mg in a sustained-release tablet dosage form. Dapagliflozin + Vildagliptin (Dapagliflozin 10mg + Vildagliptin 100mg) tablets require formulation development comprising of two APIs with appropriate excipients, blending, compression and release controlling technology. Dapagliflozin 10mg + Vildagliptin 100mg SR Tablets can be added to an established formulation for oral product range in the Pharma Franchise segment, by a professional PCD Pharma Franchise business.
The API development process involves careful qualification of the pharmaceutical APIs before final acceptance, formulation development to evaluate the stability and compatibility of APIs with selected excipient systems and formulation testing to evaluate release characteristics of the finished formulation.
The formulation for Dapagliflozin 10mg + Vildagliptin 100mg SR Tablets is selected based on the release rate to suit the product as a concept. Critical release rate characteristics such as reproducibility of the finished API dosage units are specified by means of controlled development studies.
The final composition of the formulation is established based on system compatibility tests, and selected throughout the formulation process. Established specifications define the finished API composition, and may include the following parameters: API quantity, unit strength, uniformity of API, dosage-unit uniformity, weight variation, hardness, friability, and any other quality criteria specified.
The finished formulation is subject to controlled development studies, and the formulation characteristics are established for release in a specific product release profile.
The API qualification involves testing each pharma API selected for the product against its applicable raw-material specifications to ensure suitability for the product to be manufactured. Selected tests may include identification, assay, related substances, purity, residual solvents, particle size, moisture, and other quality criteria.
Accurate dispensing of API quantities is achieved using calibrated weighing equipment, and documented dispensing procedures to ensure that the specified quantities are maintained through the batch manufacture.
The suitability of individual API blending characteristics is evaluated using a formulated API blending study, and the compatibility of API blending qualities is assessed by means of API compatibility studies.
The formulation development tests the API(s) for compatibility with excipients suitable for a tablet dosage form, and evaluates selected excipients for powder mixing, and powder granulation, if appropriate. The compatibility of APIs and excipients depends on the formulating technology, and the selected formulation.
The formulation must maintain the predefined component proportions of the two API quantities, and maintain the reproducibility of the finished API units. The required finished API unit is determined by the chosen release profile.
The finished formulation should contain the API quantities and release technology appropriate for the required product profile. API quantities are determined by the dosed component sizes, and the release technology may be a controlled release component, such as a polymeric matrix, a function of coating material(s), or other technology.
The controlled release component can be incorporated into the formulation by means of a coating process, or by means of a controlled-release matrix, according to the technological requirements of the application.
A controlled-release matrix can be achieved with the incorporation of selected polymeric or other suitable release-modifying excipients, during formulation processing. The quantity, distribution, water-absorbing capabilities, as well as processing conditions can all influence the resulting release rate.
The drug formulation can be prepared by means of dry blending, wet granulation, drying, milling, sizing, direct compression, lubrication, or other technological approaches as appropriate. Each stage of the process is under specific control to minimize the effect of input parameters on finished quality.
If a coating technology is selected, the coating equipment parameters such as spray rate, coating weight, drying conditions, and finished product temperature may all influence the resulting controlled release rate. The controlled release rate formulation quality is reflected in the finished product.
Samples of finished product can be taken from the coating process to determine application uniformity, and coating parameters such as weight gain, and appearance are used to determine if the coating process is under control before further processing.
The formulation blend or granulation is tested for uniformity, moisture content, particle size, and other controlled parameters before being compressed into final composition using tablet or capsule compression equipment.
Following API blending or granulation, the controlled-release composition is tableted or capsuled using appropriate compression, or capsule-filling equipment. Each parameter of the finished product can be regularly checked for consistency, and routine mechanical and visual inspection.
Tablet weight, weight variation, hardness, thickness, friability, appearance, and other relevant parameters can be checked during the compression process to ensure consistency of finished product parameters. Tests can be used to monitor product uniformity, and production lines can be adjusted accordingly.
The lower quantity API component may require additional blending or sampling controls to ensure that API quantity maintains the required quality.
Calibration of compression equipment, proper cleaning, and equipment repairs and maintenance using approved procedures ensure that the quantity of API contained is accurately controlled throughout production.
If controlled-release technology involves a coating, controlling parameters such as spray rate, drying temperature, coating temperature, and weight gain help ensure reproducible coating and release characteristics. Appearance, coating weight, and other coating quality parameters can be measured at regular intervals, and checked against specification.
Samples can be withdrawn from the coating process to evaluate uniformity of coating, weight gain, appearance, and other relevant parameters.
Finished-product testing of Dapagliflozin 10mg + Vildagliptin 100mg SR Tablets involves testing of both active ingredients for quality and the overall finished product for quality criteria. The finished product is tested to specification, which may include the following parameters:
Description, identification, assay of Dapagliflozin and Vildagliptin, related substances, dissolution, weight variation, dosage-unit uniformity, weight, hardness, friability, and appearance.
In addition, the release of API from the finished product may be monitored by means of a dissolution test, and the reproducibility of the product determined by means of a dosage-unit uniformity test. All analytical and testing procedures should be validated or verified as appropriate for the methodology.
The dissolution test for finished product determines the reproducibility of the release rate of API from the product. Samples can be taken throughout the designated release period, and the product standardized accordingly.
Dosage-unit uniformity results determine the API content of individual dosage units, and are used to determine whether the product maintains the desired API quantity and release rate characteristics for use as a finished product.
Laboratory analytical procedures, equipment calibration and qualification, and in-process testing are all documented in the product batch record, and these can all be used to derive the finished product specifications and release standards.
Stability testing samples of Dapagliflozin 10mg + Vildagliptin 100mg SR Tablets are determined using a designated protocol, and evaluated under defined conditions at predesignated time intervals. Any change in the appearance, dosage-unit uniformity, drug release rate, or other specifications that define the finished product can be assessed to determine whether the product remains within the specification range.
Aspects monitored during stability testing may include appearance, API (Dapagliflozin and Vildagliptin) assays, related substances, dissolution rate, hardness, friability, and other specifications to match the designated finish formulation.
The packaging used may be the same as that used for the finished product, or may be chosen according to the stability data for the specific API in the pack. Suitable blister packs, blister strips, or other protective packaging may be chosen based on the specifications established for the finished product. Packaging studies may monitor the ability of the container to protect the product from moisture, oxygen, light, or other environmental factors.
Sealing, coding, packaging-line controls, and protective properties of the packaging may all contribute to the functionality of the finished product for sale and distribution. For a professionally managed PCD Pharma Franchise Business, Dapagliflozin 10mg + Vildagliptin 100mg SR Tablets can be included in the organized portfolio of pharmaceutical products.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech